Blockage of this enzyme enhanced significant humoral and cellular pathways responses to tumor lysate vaccine and/or DCs pulsed tumor lysate, besides significant improvements showed in clinical trials with chemotherapy used 1-MT checkpoint inhibitor21,31,32, which clearly evidenced that depletion of IDO activity instantly leads to increase therapeutic susceptibility. The gene discussed is IDO1; the disease is neoplasm.